Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 3/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25425630 | 0.76 | NNMT (0.47) | NNMTHTR2AADRA2AKMT2A | |
| SCHEMBL25425626 | 0.76 | NNMT (0.47) | NNMTHTR2AADRA2AKMT2A | |
| SCHEMBL13507512 | 0.73 | NNMT (0.42) | NNMT | |
| SCHEMBL28923994 | 0.69 | CREBBP (0.52) | ACHECREBBPCHRM2CHRM1CHRM3 | |
| SCHEMBL20597761 | 0.67 | RAF1 (0.43) | CYP19A1GAA | |
| Hydrochloric Acid SCHEMBL30550489 | 0.67 | PARP1 (0.42) | ADRA1AADRA2ACHRNB4CHRNA3 | |
| SCHEMBL23075156 | 0.65 | KDM4E (0.42) | ADRA1AACHEADRA2ACYP19A1CHRM2 | |
| SCHEMBL279883 | 0.65 | TSHR (0.44) | NNMTADRA1ACREBBPTSHR | |
| SCHEMBL20747328 | 0.64 | ACHE (0.41) | ACHEGAA | |
| SCHEMBL30101393 | 0.63 | NCF1 (0.34) | ADRA1AHTR2AADRA2ANCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666898-B2 | Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors | ILYPSA, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20070135385-A1 | Methyl indoxam; obesity; dietectics; antidiabetic agents; insulin resistance; non-insulin dependent diabetes; glucose intolerance; hypercholesterolemia; hypertriglyceridemia; anticholesterol agents; metabolic disorders; foods;bioavailability; side effect reduction | ILYPSA, INC. | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135385-A1 | Methyl indoxam; obesity; dietectics; antidiabetic agents; insulin resistance; non-insulin dependent diabetes; glucose intolerance; hypercholesterolemia; hypertriglyceridemia; anticholesterol agents; metabolic disorders; foods;bioavailability; side effect reduction | GPR119, INMT, PNLIP | NNMT 51/4885ADRA1A 1988/4885ACHE 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.